[Clinical efficacy of myocardial cytoprotector trimetazidine in peri- and postmenopausal women with ischemic heart disease].
Efficacy of 3-12 month use of trimetazidine hydrochloride combined with verapamil was assessed in postmenopausal women with effort angina by repetitive exercise tests, ECG monitoring and echocardiography. The use of trimetazidine was associated with augmentation of antianginal and antiischemic action of verapamil, improvement of systolic and diastolic left ventricular function, decrease in frequency of hospitalizations because of exacerbation of ischemic heart disease. These effects were evident in all age groups throughout the period of observation and did not depend on the ischemic heart disease duration.
Izhevsk State Medical Academy.
A D
AD
Churshin
L T
LT
Pimenov
D000368:Aged; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000503:physiopathology; D017698:Postmenopause; D017697:Premenopause; D016896:Treatment Outcome; D014292:Trimetazidine / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*; D014700:Verapamil / Q000627:therapeutic use*
D014665:Vasodilator Agents; D014700:Verapamil; D014292:Trimetazidine